CELLINK will help develop 3D bioprinted personalised scaffolds for tissue regeneration of ankle joint s as part of the TRIANKLE project

The TRIANKLE consortium – made up of 12 European organisations, will develop 3D bioprinted personalised scaffolds for tissue regeneration of ankle joints. This ambitious research project in regenerative medicine has an overall budget of €5.9M and will be developed over 4 years, starting January 2021. CELLINK´s portion of the grant is. €622,000 of which EU accounts for 100 percent of the costs. The consortium aims to create innovative personalised collagen- and gelatine-based implants manufactured with 3D technology for patients with tendinopathies such as Achilles tendon partial ruptures and cartilage injuries.

TRIANKLE consortium consists of a team of 12 organisations covering the complete spectrum from advanced research to the market. Its main strength relies on the combination of highly skilled partners with proven track records in biomaterials for regenerative applications and 3D bioprinting technology. Partners are also devoted to social engagement and dissemination of results to healthcare professionals and, ultimately, potential patients. A total of 12 organisations from 5 different countries (Germany, Spain, Sweden, the Netherlands, and the United Kingdom) make up the TRIANKLE consortium. The partnership includes one industry partner (Naturin Viscofan GmbH), three SMEs (CELLINK AB, Cambridge Nanomaterials Technology, and Gradocell SL), two research centres (Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. and Acondicionamiento Tarrasense Associacion), three universities (University of Stuttgart, Universidad del País Vasco and Eindhoven University of Technology), two non-profit organisations (Futbol Club Barcelona Asociacion FCB and Osteoarthritis Foundation International OAFI) and one healthcare institution (Fundacio Clinic per a la Recerca Biomedica). The TRIANKLE project coordinator is Naturin Viscofan GmbH.

CELLINK is thrilled to be a part of the TRIANKLE project and contribute to unlocking the potential of innovative 3D printing technology for regenerative medical applications and ultimately enable the commercialization of 3D-printed personalised regenerative solutions. Furthermore, the innovation potential of TRIANKLE lies in the launching of the technological platform that will enable the development of future regenerative therapies of joint tissues in weight-bearing joints.

For further information, please contact:

Erik Gatenholm, CEO                                                                            Gusten Danielsson, CFO                             
Phone (Sweden): +46 73 267 00 00                                                       Phone (Sweden): +46 70 991 86 04      
Phone (US): +1 (650) 515 5566                                                              Phone (US): +1 (857) 332 2138
[email protected]                                                                            Email: [email protected]                               

This information was submitted for publication, through the agency of the contact persons set out above, on November 9, 2020 at 09:00 a.m. (CET).


Founded in 2016, CELLINK is a global life-science company that provides technologies, products and services to create, understand, and master cell and molecular biology. With a focus on the application areas of bioprinting, analysis, and liquid handling and bioprocessing, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,000 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 55 countries, and have been cited in more than 150 publications. CELLINK is creating the future of medicine.

Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.

Latest press releases